BMS-986278

BMS-986278

BMS-986278 is an experimental drug currently under development by Bristol-Myers Squibb, a global biopharmaceutical company. The drug is being studied for its potential use in the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).

Overview

BMS-986278 is a lysophosphatidic acid receptor 1 (LPA1) antagonist. LPA1 is a G protein-coupled receptor that plays a crucial role in the development of fibrosis in various organs. By blocking the action of LPA1, BMS-986278 is expected to inhibit the progression of fibrotic diseases.

Clinical Trials

As of 2021, BMS-986278 is in Phase 2 of clinical trials. The drug has shown promising results in preclinical studies, demonstrating its potential to reduce fibrosis and improve organ function. However, further research is needed to confirm these findings and determine the drug's safety and efficacy in humans.

Potential Applications

The primary focus of BMS-986278 research is its potential use in treating IPF and NASH. Both of these conditions are characterized by the buildup of fibrous tissue, which can lead to organ damage and failure. By targeting the LPA1 receptor, BMS-986278 may be able to slow or halt the progression of these diseases.

See Also

• Bristol-Myers Squibb
• Idiopathic pulmonary fibrosis
• Non-alcoholic steatohepatitis
• Clinical trial
• Lysophosphatidic acid receptor 1